HIV Waiting Room: Newly diagnosed transgender woman

Released On
October 31, 2019

Expires On
March 31, 2021

Media Type

Completion Time
30 minutes

HIV Specialists


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Global Education Group and Integritas Communications.


Supported by an educational grant from Gilead Sciences, Inc.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for infectious disease and HIV specialist physicians and other clinicians involved in the care of patients with HIV infection.

Statement of Need/Program Overview

Transgender patients face an increased risk of contracting HIV, and for those who are HIV positive, a unique set of challenges in treatment. This population achieves viral suppression less frequently than cisgender populations, making it essential for clinicians to understand the factors that determine this gap and optimal strategies to improve patient care.

This case-based, interactive activity focuses on transgender women with HIV, creating a clinical scenario addressing treatment initiation, incorporating gender-affirming hormone therapy into care, adherence, common comorbidities, and strategies to create a gender-affirming practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement strategies to overcome the barriers to and facilitate the benefits of timely HIV treatment initiation, including consideration of rapid ART protocols
  • Describe the HIV treatment considerations unique to transgender women to improve engagement in care and optimize viral suppression


Bruce Hinton PA-C, AAHIVMS

CrescentCare Health and Wellness Center
New Orleans, Louisiana

Carole Pindaro, APRN

New Orleans, Louisiana

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Bruce Hinton PA-C, AAHIVMS

  • Nothing to disclose

Carole Pindaro, APRN

  • Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Lindsay Borvansky: Nothing to disclose

Andrea Funk: Nothing to disclose

Liddy Knight: Nothing to disclose

Ashley Cann: Nothing to disclose

Gena Dolson, MS: Nothing to disclose

Stacey JP Ullman, MHS: Nothing to disclose

Jim Kappler, PhD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 65% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 65%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.

There is no fee for this educational activity.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or